Cytokinetics CYTK Non Cash Interest Expense On Liabilities Related To Revenue Participant Right Purchase Agreement
Non Cash Interest Expense On Liabilities Related To Revenue Participant Right Purchase Agreement at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept cytk:NonCashInterestExpenseOnLiabilitiesRelatedToRevenueParticipantRightPurchaseAgreement.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's non cash interest expense on liabilities related to revenue participant right purchase agreement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's non cash interest expense on liabilities related to revenue participant right purchase agreement?
- Cytokinetics (CYTK) reported non cash interest expense on liabilities related to revenue participant right purchase agreement of $18.82M in Q1 2026.
- How has Cytokinetics's non cash interest expense on liabilities related to revenue participant right purchase agreement changed year-over-year?
- Cytokinetics's non cash interest expense on liabilities related to revenue participant right purchase agreement increased by 33.4% year-over-year, from $14.1M to $18.82M.
- What is the long-term trend for Cytokinetics's non cash interest expense on liabilities related to revenue participant right purchase agreement?
- Over 4 years (2021 to 2025), Cytokinetics's non cash interest expense on liabilities related to revenue participant right purchase agreement has grown at a 45.6% compound annual growth rate (CAGR), from $13M to $58.37M.
- What does non cash interest expense on liabilities related to revenue participant right purchase agreement mean?
- Non-cash interest costs associated with revenue-sharing financing agreements.
- How do you interpret non cash interest expense on liabilities related to revenue participant right purchase agreement?
- An increase suggests higher non-cash financing costs, which may indicate future revenue dilution.
- How does non cash interest expense on liabilities related to revenue participant right purchase agreement compare across companies?
- Common in biotech companies using royalty-based financing or revenue interest structures.